When examining 25 years of pharmaceutical sales data in the United States, a clear picture emerges: a handful of drugs have generated tens of billions of dollars in revenue, reshaping the industry and transforming how we understand drug development, patent strategy, and clinical research. Using data from IQVIA, the following list ranks the 10 best-selling drugs US markets produced between 1992 and 2017, measured by total revenue accumulated over that period. What drove their success goes beyond the drugs themselves.<\/p>\n
Launch timing, demonstrated clinical need, scientific differentiation, and sustained marketing efforts all played a decisive role. The best-selling drugs US history has recorded share one common foundation: rigorous clinical trial development that proved their value before they ever reached patients.<\/p>\n
Understanding which drugs became blockbusters and why also matters for clinical research organizations like FOMAT. Each of the drugs on this list passed through rigorous Phase I through Phase IV clinical trials before reaching patients. Their stories reflect what well-executed research can ultimately produce.<\/p>\n
The ranking below is based on cumulative US revenue from 1992 to 2017, compiled by IQVIA, one of the most authoritative sources of pharmaceutical market data. The list spans multiple therapeutic categories including cardiovascular disease, immunology, respiratory conditions, oncology support, and mental health. Some of these drugs are now off patent and available as generics or biosimilars. Others continue to generate significant revenue even decades after their initial approval.<\/p>\n
Pfizer’s Lipitor holds the top position with $94.67 billion in cumulative US sales. Originally developed by Warner-Lambert and approved by the FDA in late 1996, Lipitor was not the first statin to reach the market, yet it became the most commercially successful one in history. Its rise was fueled by large scale clinical studies that demonstrated its ability to reduce not just cholesterol levels but also the incidence of heart attacks. As noted by the Mayo Clinic<\/a>, statins as a drug class have become one of the most widely prescribed treatments for reducing cardiovascular risk.<\/p>\n Growing public awareness around cardiovascular risk, combined with Pfizer’s marketing strength and the FDA’s 1997 relaxation of direct to consumer advertising rules, helped elevate Lipitor to dominance. Although sales declined sharply following patent expiration in late 2011, the drug still generated $1.92 billion in 2017 revenue.<\/p>\n AbbVie’s Humira follows with $75.72 billion in cumulative US sales, making it the clear successor to Lipitor’s throne. Approved on the last day of 2002, it was the first fully human monoclonal antibody to reach patients, initially for rheumatoid arthritis. Two competing TNF-alpha inhibitors, Enbrel and Remicade, had already been on the market for over four years at that point.<\/p>\n Humira distinguished itself through a more convenient self-injection format versus intravenous administration, as well as through an aggressive expansion of approved indications that came to include psoriatic arthritis, Crohn’s disease, and juvenile idiopathic arthritis.<\/p>\nHumira: the new king of best-selling drugs US pharma has ever seen<\/strong><\/h3>\n